Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 735 across all filing types
Latest filing 2021-09-28 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
公司章程（草案）
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association for Xinxiang Tuoxin Pharmaceutical Co., Ltd. It includes comprehensive sections on company purpose, share issuance, shareholder rights, shareholder meetings, board of directors, and other governance matters. It is a legal and governance document outlining the internal rules and structure of the company rather than a financial report, announcement, or meeting material. There is no indication that this is an annual report, earnings release, proxy statement, or any other financial or regulatory filing. The content aligns with governance information about the company's internal rules and board structure.
2021-09-28 Chinese
中国证监会关于同意公司首次公开发行股票注册的批复
Capital/Financing Update Classification · 95% confidence The document is an official approval from the China Securities Regulatory Commission regarding the registration for the company's initial public offering (IPO) and listing on the Growth Enterprise Market. It references regulatory laws and the registration approval for the first public issuance of shares. This is a formal regulatory approval notice related to capital raising and stock issuance, not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document is short and formal, consistent with a financing update rather than a full report or announcement of a report publication.
2021-09-28 Chinese
2021年1-6月审阅报告
Audit Report / Information Classification · 95% confidence The document is titled as an "审阅报告" which translates to "Review Report" and includes detailed financial statements such as consolidated balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements for the period ending June 30, 2021. The report is issued by a certified public accounting firm and explicitly states it is a review (审阅) rather than an audit, providing limited assurance on the financial statements. The presence of comprehensive financial data and the nature of the report indicate it is a standalone audit-related report but not a full annual report. It is not a full audit opinion but a review report, which fits the category of Audit Report / Information (AR). The document length is substantial (15,000 characters), and it contains actual financial data, so it is not merely an announcement or certification. Therefore, the correct classification is AR with high confidence.
2021-09-28 Chinese
首次公开发行股票并在创业板上市提示公告
Capital/Financing Update Classification · 95% confidence The document is titled as a "首次公开发行股票并在创业板上市提示公告" which translates to "Initial Public Offering (IPO) and Listing on the ChiNext Market Notice Announcement." It details the IPO process, including subscription dates, pricing, investor qualifications, allotment, and risk disclosures. It references regulatory approvals from the Shenzhen Stock Exchange and China Securities Regulatory Commission. The document is a detailed announcement about the IPO process and related investor instructions rather than a financial report or earnings release. It is not a full annual or interim report, nor a call transcript or management report. It is also not a proxy, voting result, or remuneration report. The document is a formal announcement related to capital raising and issuance of new shares. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (8612 characters) and content confirm it is a substantive announcement, not a brief notice or report publication announcement.
2021-09-28 Chinese
审计报告及财务报表
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It contains detailed audit opinions, key audit matters, responsibilities of management and auditors, and extensive financial statements including balance sheets, profit and loss statements, cash flow statements, and notes. The document is about the audit of financial statements for the years ending 2018, 2019, and 2020. It is issued by a certified public accounting firm and includes detailed audit procedures and findings. The length is substantial (15,000 characters), indicating it is the full audit report, not just an announcement or certification. Therefore, this document fits the category of an Audit Report / Information (AR).
2021-09-28 Chinese
公司控股股东、实际控制人对招股说明书的确认意见
Regulatory Filings Classification · 95% confidence The document is a confirmation opinion from the controlling shareholder and actual controller regarding the prospectus for the company's initial public offering (IPO) on the Growth Enterprise Market. It is a short statement confirming the accuracy and completeness of the prospectus, signed by the controlling shareholder. The document length is only 301 characters, indicating it is not the prospectus itself but a confirmation related to it. This fits the pattern of a Regulatory Filing (RNS) as it is a compliance-related statement rather than a full report or financial document.
2021-09-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.